脂蛋白和心力衰竭:一个系统的审查
Walter Masson1, Leandro Barbagelata2, Augusto Lavalle-Cobo3
1Cardiology Department, Hospital Italiano de Buenos Aires, Perón 4190, Ciudad Autónoma de Buenos Aires, C1199ABB, Buenos Aires, Argentina. walter.masson@hospitalitaliano.org.ar.
Heart failure reviews
|July 19, 2023
概括
升高的脂蛋白 (a) [Lp (a) ]水平可能与心力衰竭 (HF) 有关. 这项对73,410名患者的系统性审查表明了积极的关联,尽管需要更多的研究来证实这种关系.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 流行病学 流行病学
背景情况:
- 脂蛋白 (Lp) 是动脉样硬化心血管疾病的已知危险因素.
- Lp(a) 水平与心力衰竭 (HF) 之间的关联仍然存在争议,研究不足.
研究的目的:
- 系统地审查和评估Lp(a) 水平与心力衰竭之间的关联.
- 综合当前关于Lp (a) 的证据,将其作为HF的潜在风险因素或标志物.
主要方法:
- 系统的文献审查遵循PRISMA指南.
- 包括8项研究,共计73,410名患者.
- 对前性队列和评估Lp (a) 和HF终点的横截面研究的分析.
主要成果:
- 大多数包括在内的研究报告说,Lp(a) 水平和心力衰竭之间存在积极的关联.
- 有证据表明,较高的Lp(a) 与发生的HF,HF住院治疗或左心室喷射率降低之间存在潜在的联系.
- 对于特定子组的数据有限,例如HF病因或左心室功能障碍状态.
结论:
- 这一系统性审查表明,升高的Lp(a) 水平与心力衰竭之间可能存在积极的关系.
- 需要进一步的研究来阐明Lp (a) 在各种HF表型和病因学中的复杂作用.
相关概念视频
Atherosclerosis I: Introduction
11
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
11
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure I: Introduction
20
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
20
Heart Failure IV: Classification and Diagnostic Evaluation
20
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465


